Inactive Instrument

Analyst Reco. CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Barclays Downgrades CinCor Pharma to Equal-Weight Rating From Overweight, Adjusts Price Target to $31 From $22	23-01-12	MT
Morgan Stanley Adjusts Price Target on CinCor Pharma to $30 From $22, Maintains Equal-Weight Rating	23-01-10	MT
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	23-01-09	MT
Barclays Starts CinCor Pharma at Overweight With $22 Price Target	22-12-07	MT
Goldman Sachs Slashes Price Target on CinCor Pharma to $26 From $64, Keeps Buy Rating	22-11-29	MT
LifeSci Capital Lowers Price Target on CinCor Pharma to $52 From $64, Reiterates Outperform Rating	22-11-29	MT
Piper Sandler Slashes Price Target on CinCor Pharma to $53 From $73, Reiterates Overweight Rating	22-11-29	MT
Oppenheimer Downgrades CinCor Pharma to Market Perform From Outperform	22-11-29	MT
Morgan Stanley Downgrades CinCor Pharma to Equalweight From Overweight, Adjusts Price Target to $22 From $60	22-11-29	MT
Goldman Sachs Starts CinCor Pharma at Buy With $67 Price Target	22-10-28	MT
LifeSci Capital Initiates CinCor Pharma at Outperform With $64 Price Target	22-09-26	MT
Morgan Stanley Boosts Price Target on CinCor Pharma to $60 From $45, Maintains Overweight Rating	22-09-09	MT
ANALYST RECOMMENDATIONS : Snowflake, Vipshop, UIta Beauty, VF, Advance Auto Parts...	22-08-22
Piper Sandler Starts CinCor Pharma at Overweight With $73 Price Target	22-08-22	MT
Morgan Stanley Adjusts CinCor Pharma's Price Target to $45 from $31, Keeps Overweight Rating	22-08-09	MT
Oppenheim Raises Price Target for CinCor Pharma to $60 From $35, Maintains Outperform Rating	22-08-08	MT
Oppenheimer Adjusts CinCor Pharma Price Target to $35 From $30, Maintains Outperform Rating	22-07-21	MT
Morgan Stanley Adjusts CinCor Pharma's Price Target to $31 from $27, Keeps Overweight Rating	22-07-15	MT
Oppenheimer Initiates Coverage on CinCor Pharma With Outperform Rating, $30 Price Target	22-02-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Analyst Reco.

Filters